TOPIC CALL 2 Q and A_Ph II.pdf

Approved for Public Release

Questions Answers Q1: Are there minimum percent time commitments or other requirements that need to be met by Key Personnel? Reference: 4.8.2.1.1.3 Credentials (p.19)

A1: No

Q2: Does the time-phased expenditure plan need to broken out by task? Reference:

4.8.2.1.1.4 Project Management (p.20)

A2: No

Q3: Is the SOW included in the page count? Reference: 4.8.2.1.2 BOE (p.21) A3: No

Q4: Does DTRA specify labor category definitions? Reference: 4.8.2.1.2 BOE (p.21) A4: No

Q5: CBA-01: Are there any required DTRA project meetings that we should plan to travel to attend in person? Reference: 4.8.2.1.2 BOE (p.21)

A5: Yes, please plan to travel to DTRA for an In-Person Review (IPR) one year after kick-off. In addition, please plan to travel to the next DTRA S&T Conference in 2024 or 2025, location to be determined.

Q6: Is the "investigator" in this case the key personnel? "This information must be included for each investigator listed in the proposal." Reference: 4.8.2.3.8 Statement of Current and Pending Support

A6: This information is not required for all key personnel. Information should be provided for the Offeror, any proposed sub-contractor and principal investigator(s).

Q7: For costing purposes, would the government provide an anticipated start date?

Reference: 4.8.2.2 Cost Volume

A7: Awards are estimated to occur in Government Fiscal Year 2024, 3rd quarter.

Q8: May an offeror propose to perform software development work using existing internal computing resources that are not currently FedRAMP-authorized if the development work does not exceed IL2? Reference: 4.8.2.3.14 Information Technology

A8: Yes, an offeror may propose to perform software development work using existing internal computing resources that are not currently FedRAMP-authorized for development work that does not exceed Impact Level (IL)2; however, data sets provided by the Government for analysis will likely be deemed IL4.

Q9: Does all software development work for Topic Call 2 "CBA 01 - Detection:

Bioinformatics Capabilities for the Field and Beyond" need to be done on FedRAMP authorized systems? Reference: 4.8.2.3.14 Information Technology

A9: No. All software development work for for Topic Call 2 "CBA 01 - Detection: Bioinformatics Capabilities for the Field and Beyond" does not need to be done on FedRAMP authorized systems; however, the work proposed must be compliant with DFARS clause 252.204-7012 Safeguarding Covered Defense Information and Cyber Incident Reporting.

Q10: CBS-02: Are there particular agents of interest in each of the three agent class? A10: DTRA cannot provide an answer to this question at this time. DTRA would prefer that no specific agents be named in the proposal. If chosen for award, then DTRA and the offeror would have discussions at the appropriate level to share such information.

Q11: CBS-02: Would there be expectation to evaluate efficacy in vivo against at least one agent in each of the three classes?

A11: There is an expectation to evaluate in vivo efficacy against at least one agent in each of two classes, but it would be good to know what costs and time would be to cover at least one agent of each of the three classes.

Q12: CBS-02: We would like to recommend limiting to one comparator for the in vitro and in vivo screening. We would like to recommend PB as the comparator. Is this acceptable?

A12: DTRA is willing consider one comparator, but is not willing to specify a comparator at this time. The offeror should submit what they deem appropriate for the submission of the Phase II proposal.

Q13: CBS-02: Would DTRA like to proceed with the Guinea Pig models for efficacy testing, or would it be acceptable to pivot to the KI/KO mouse model?

A13: Yes, it is acceptable to use the KIKO Mouse model for in vivo efficacy testing.

Sheet1